Clinical Trials Directory

Trials / Completed

CompletedNCT01524640

Bridging Study for Killed Oral Cholera Vaccine in Ethiopia

A Randomized, Double-blind, Controlled Trial to Evaluate the Safety and Immunogenicity of Killed Bivalent (o1 and o139) Whole-cell Based Oral Cholera Vaccine (Shanchol®) in Healthy Individuals in Ethiopia

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
216 (actual)
Sponsor
International Vaccine Institute · Academic / Other
Sex
All
Age
1 Year
Healthy volunteers
Accepted

Summary

This is a randomized, double blind, placebo controlled trial to confirm the safety and determine the immune response of the killed oral cholera vaccine in healthy adults and children in Ethiopia.

Detailed description

This study serves as a bridging trial to evaluate the safety and immunogenicity of a two dose regimen of the WC-OCV (Shanchol®) in Ethiopian population. In order to assess whether the bivalent killed oral cholera vaccine may be used safely among those who are most at risk for cholera, we need to determine the safety and immunogenicity of the killed oral cholera vaccine. The vaccine was evaluated in a large number of human subjects in India Vietnam, and Bangladesh, in which it has demonstrated safety, immunogenicity, and clinical protective efficacy. Though we do not expect the vaccine to act differently in the Ethiopian population, we aim to confirm our presumptive understanding that two doses of WC-OCV is safe and immunogenic in healthy volunteers at one year and above (exclusive of pregnant women). Findings from this study can pave the way for the possible use of the killed whole cell oral cholera vaccine in both endemic and outbreak settings at a larger scale.

Conditions

Interventions

TypeNameDescription
BIOLOGICALKilled Bivalent (O1 and O139) whole cell oral cholera vaccine1.5 ml single dose oral administration on day 0 and day 14
BIOLOGICALPlacebo1.5 ml oral administration on day 0 and day 14

Timeline

Start date
2012-12-01
Primary completion
2013-08-01
Completion
2013-08-01
First posted
2012-02-02
Last updated
2015-05-04

Locations

1 site across 1 country: Ethiopia

Source: ClinicalTrials.gov record NCT01524640. Inclusion in this directory is not an endorsement.